Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8546608 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(1 year, 4 months from now) | |
US8003819 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
US8530694 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
US7687662 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
US8859504 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(6 years from now) | |
US7442830 | TAKEDA PHARMS USA | Proteasome inhibitors |
Nov, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9233115 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(1 year, 4 months from now) | |
US8871745 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
US9175017 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 20, 2022 |
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
47
United States
15
China
12
Korea, Republic of
12
Hong Kong
10
Japan
10
European Union
9
Israel
8
Taiwan, Province of China
7
New Zealand
7
Argentina
6
Brazil
6
Peru
6
EA
6
South Africa
5
Mexico
4
Portugal
4
Malaysia
4
Spain
4
Philippines
4
Canada
4
Ukraine
4
Denmark
3
Singapore
3
Croatia
3
Costa Rica
3
Norway
3
Cyprus
3
Slovenia
3
Poland
3
Georgia
3
Australia
3
Ecuador
2
Chile
2
RS
1
Germany
1
Colombia
1
Dominican Republic
1
Austria
1
Morocco
1
Tunisia
1
Lithuania
1
Hungary
1
Luxembourg
1
Iceland
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic